Skip to main content
Amphastar Pharmaceuticals, Inc. logo

Amphastar Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMPH ISIN · US03209R1032 LEI · 54930055TH0ZLSAQMJ38 US Manufacturing
Open in API
Filings indexed 918 across all filing types
Latest filing 2014-06-25 Director's Dealing
Country US United States of America
Listing US AMPH

About Amphastar Pharmaceuticals, Inc.

https://amphastar.com/

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing technically challenging medications. Its portfolio includes generic and proprietary injectable, intranasal, and inhalation products. The company specializes in complex medications such as biologics derived from living cells, proteins, and interchangeable biosimilars. Amphastar also develops innovative drug delivery systems and proprietary technological platforms for various routes of administration.

Recent filings

Filing Released Lang Actions
3
Director's Dealing
2014-06-25 English
3
Director's Dealing
2014-06-25 English
Capital/Financing Update 2014
Capital/Financing Update Classification · 95% confidence The document is a letter from underwriters requesting acceleration of the effective date of a Registration Statement on Form S-1 for Amphastar Pharmaceuticals, Inc. It references the Securities Act of 1933 and Rule 461 and Rule 460, which are related to securities offerings and registration statements. The content is about the procedural aspects of a public offering and distribution of preliminary prospectuses, not a financial report or earnings release. The document length is short (2776 characters) and it is a formal correspondence related to a capital raising process. This fits the category of Capital/Financing Update (CAP), as it concerns the registration and offering of shares, which is a financing activity.
2014-06-20 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from Amphastar Pharmaceuticals, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and requests the SEC to declare the Registration Statement effective by a certain date and time. The document is a formal request related to the registration process for securities, not a financial report, earnings release, or other types of filings. It is a regulatory procedural filing related to the registration statement effectiveness, which fits best under Regulatory Filings (RNS). The document length is short (2636 characters), and it is not a report itself but a correspondence/request to the SEC.
2014-06-20 English
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2014-06-19 English
S-1/A
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 3 to Form S-1 Registration Statement filed with the SEC by Amphastar Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes details about the registration, expenses related to the offering, indemnification of directors and officers, and recent sales of unregistered securities. There is no indication that this is a financial report like an Annual Report or Quarterly Report, nor is it a transcript, governance report, or other categories. It is clearly a regulatory filing related to securities registration and offering. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual filing document itself.
2014-06-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.